PrimeRFP
PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91019D00021EO 14398 preclinical efficacy and intermediate — University of Texas M D Anderson Cancer Center

University of Texas M D Anderson Cancer Center holds $28.1M across 39 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 3 related awards in the incumbent pipeline. Set-aside status: NONE.

Nih Nci
Awarding office
University of Texas M D Anderson Cancer Center
Recipient
—
Estimated value
AN12
PSC
NONE
Set-aside

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs University of Texas M D Anderson Cancer Center — $90

Contract facts

NONE
Contract number75N91019D00021
AgencyNih Nci
Awarding officeNih Nci
Awarding agencyDepartment of Health and Human Services (HHS)
Funding agencyDepartment of Health and Human Services (HHS)
IncumbentUniversity of Texas M D Anderson Cancer Center
UEIS3GMKS8ELA16
PSCAN12
Related solicitationN01CN7701918

EO 14398 PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS is a federal NONE award for Nih Nci held by University of Texas M D Anderson Cancer Center. Estimated value —. Related solicitation N01CN7701918.

EO 14398 PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS

Incumbent footprint

Public record

University of Texas M D Anderson Cancer Center — $28.1M obligated across 39 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($28.1M) · all agencies
Department of Health and Human Services (HHS)$27.0M · 96%Department of Veterans Affairs (VA)$1.1M · 4%

Related awards

Same incumbent
75N91019F00131
REPURPOSING OF MACROLIDE ANTIBIOTIC CLARITHROMYCIN FOR THE PREVENTION OF LUNG AND BREAST C…
$8.7M
Apr 14, 2027
36C24524P0903
MED PHYSICS PEER REVIEW SERVICES
$1.1M
Sep 30, 2027
75N97021C00001
OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC)
$8.7M
Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract 75N91019D00021?

75N91019D00021 (EO 14398 preclinical efficacy and intermediate) is a Nih Nci award with an estimated value of —, currently held by University of Texas M D Anderson Cancer Center. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91019D00021?

Nih Nci awarded 75N91019D00021 to University of Texas M D Anderson Cancer Center.

Who is the incumbent on 75N91019D00021?

University of Texas M D Anderson Cancer Center is the incumbent with $28.1M across 39 related awards in SCOUT’s public footprint.

When does University of Texas M D Anderson Cancer Center’s 75N91019D00021 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N91019D00021 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N91019D00021